Trimetazidine for Improved Left Ventricular Functions and Reduced Inflammation in Type 2 Diabetes Mellitus Patients

This study focuses on patients with type 2 diabetes mellitus who often experience a common complication known as subclinical diastolic dysfunction. This condition is an early phase of diabetic cardiomyopathy, which can increase mortality rates and potentially lead to heart failure. The study aims to investigate the effects of Trimetazidine, a drug typically used to treat coronary artery disease, on this specific condition. Trimetazidine is known for its positive effects on energy metabolism in heart failure, and the hypothesis is that it may improve clinical outcomes for patients with diabetic cardiomyopathy, especially when applied in the early stages. During this phase 2 treatment study, participants will receive Trimetazidine. The study's primary outcome is to measure changes in left ventricular functions from the baseline after 3 months of treatment. These changes will be assessed using echocardiographic and tissue doppler evaluation, which are non-invasive methods to monitor heart function. The study aims to understand if Trimetazidine can improve heart health in patients with type 2 diabetes mellitus and subclinical diastolic dysfunction.